Helping people who have suffered Reglan side effects after taking products containing the drug metoclopramide and representing individuals who have developed Tardive Dyskinesia in filing a Reglan lawsuit.
It has recently been reported that the drug Metoclopramide (also referred to by the brand name Reglan) which is prescribed to treat gastrointestinal disorders (GERD) and nausea has been linked to the serious movement disorder tardive dyskinesia. Reglan has been prescribed not only for acid reflux, but also for women who are pregnant and experiencing morning sickness, breastfeeding mothers, infants and children and for nausea associated with migraines. On January 26, 2009 the FDA issued an alert warning against chronic use of metoclopramide containing drugs and requiring a boxed warning. Reglan side effects tardive dyskinesia and similar drug induced movement disorders are characterized by rarely reversible symptoms that include random movements in the tongue, lips or jaw as well as facial grimacing, movements of arms, legs, fingers and toes along with swaying movements of the trunk or hip.
Metoclopramide is available in several forms including:
It is estimated that more than two million people in the United States use products containing metoclopramide. According to the FDA: "Recently published analyses suggest that metoclopramide is the most common cause of drug-induced movement disorders. Another analysis of study data by the FDA showed that about 20 percent of patients in that study who used metoclopramide took it for longer than three months. The FDA has also become aware of continued spontaneous reports of tardive dyskinesia in patients who used metoclopramide, the majority of whom had taken the drug for more than three months." We represent all Reglan lawsuit clients on a contingency basis which means that there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please call toll free at 1-844-529-8255 or fill out our short online contact form on this page.